Psychedelic Medicine Is Coming. The Law Isn’t Ready

July 31, 2019

(Scientific American) – In March, the Food and Drug Administration approved esketamine, a drug that produces psychedelic effects, to treat depression—the first psychedelic ever to clear that bar. Meanwhile the FDA has granted “breakthrough therapy” status—a designation that enables fast-tracked research—to study MDMA (also called “ecstasy”) as a treatment for post-traumatic stress disorder and psilocybin as a treatment for major depression.While these and other psychedelic drugs show promise as treatments for specific illnesses, FDA approval means doctors could also prescribe them for other, “off-label” purposes—including enhancing the quality of life of people who do not suffer from any disorder.

Recommended Reading